Literature DB >> 19019175

Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas.

Takao Nakagawa1, Kazunori Ido, Takahiro Sakuma, Hiroaki Takeuchi, Kazufumi Sato, Toshihiko Kubota.   

Abstract

We studied the expression of O(6)-methylguanine-DNA methyltransferase (O(6)-MGMT), P-glycoprotein (Pgp), and multidrug resistance protein-1 (MRP-1) in 23 glioblastomas using RT-PCR, methylation-specific PCR, and immunohistochemistry, and analyzed their association with overall patient survival. Univariate analysis of collected data demonstrated that the expressions of O(6)-MGMT and MRP-1 detected by immunohistochemistry, in addition to the consistent factors, including preoperative Karnofsky performance scale (KPS), radical surgery, and tumor location and extension, were significant prognostic factors for the overall survival (OS) of patients with glioblastoma, who received nimustine (ACNU)-based chemotherapy in association with surgery and radiotherapy. Among them, following multivariate analysis, preoperative KPS, radical surgery, tumor location, and the expression of O(6)-MGMT remained as significant prognostic factors. These findings suggest that immunohistochemical analysis of O(6)-MGMT in patients with glioblastoma can be a useful method to predict the effects of chemotherapy and identify alternative chemotherapeutic regimens for O(6)-MGMT-positive patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19019175     DOI: 10.1111/j.1440-1789.2008.00983.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  18 in total

Review 1.  MGMT testing allows for personalised therapy in the temozolomide era.

Authors:  A Dullea; L Marignol
Journal:  Tumour Biol       Date:  2015-10-30

2.  Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas--an assessment of 3 new variables in predicting clinical outcome.

Authors:  Linda R Margraf; Lynn Gargan; Yasmeen Butt; Nirupa Raghunathan; Daniel C Bowers
Journal:  Neuro Oncol       Date:  2011-06-08       Impact factor: 12.300

3.  O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.

Authors:  Yukihiko Sonoda; Michiko Yokosawa; Ryuta Saito; Masayuki Kanamori; Yoji Yamashita; Toshihiro Kumabe; Mika Watanabe; Teiji Tominaga
Journal:  Int J Clin Oncol       Date:  2010-03-16       Impact factor: 3.402

4.  Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids.

Authors:  Jesper Kolenda; Stine Skov Jensen; Charlotte Aaberg-Jessen; Karina Christensen; Claus Andersen; Nils Brünner; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2010-09-11       Impact factor: 4.130

5.  Determination of the methylation status of MGMT in different regions within glioblastoma multiforme.

Authors:  Mark G Hamilton; Gloria Roldán; Anthony Magliocco; John B McIntyre; Ian Parney; Jacob C Easaw
Journal:  J Neurooncol       Date:  2010-07-21       Impact factor: 4.130

6.  The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells.

Authors:  Ml Pinzón-Daza; R Garzón; Po Couraud; Ia Romero; B Weksler; D Ghigo; A Bosia; C Riganti
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

7.  Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.

Authors:  Shadi Lalezari; Arthur P Chou; Anh Tran; Orestes E Solis; Negar Khanlou; Weidong Chen; Sichen Li; Jose A Carrillo; Reshmi Chowdhury; Julia Selfridge; Desiree E Sanchez; Ryan W Wilson; Mira Zurayk; Jonathan Lalezari; Jerry J Lou; Laurel Ormiston; Karen Ancheta; Robert Hanna; Paul Miller; David Piccioni; Benjamin M Ellingson; Colin Buchanan; Paul S Mischel; Phioanh L Nghiemphu; Richard Green; He-Jing Wang; Whitney B Pope; Linda M Liau; Robert M Elashoff; Timothy F Cloughesy; William H Yong; Albert Lai
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

Review 8.  MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry.

Authors:  Sofia Mason; Kerrie McDonald
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-18       Impact factor: 4.553

9.  Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer.

Authors:  Shigeru Horiguchi; Hidenori Shiraha; Teruya Nagahara; Jyunnro Kataoka; Masaya Iwamuro; Minoru Matsubara; Shinichi Nishina; Hironari Kato; Akinobu Takaki; Kazuhiro Nouso; Takehiro Tanaka; Koichi Ichimura; Takahito Yagi; Kazuhide Yamamoto
Journal:  Mol Oncol       Date:  2013-04-23       Impact factor: 6.603

10.  MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.

Authors:  Consolación Melguizo; Jose Prados; Beatriz González; Raul Ortiz; Angel Concha; Pablo Juan Alvarez; Roberto Madeddu; Gloria Perazzoli; Jaime Antonio Oliver; Rodrigo López; Fernando Rodríguez-Serrano; Antonia Aránega
Journal:  J Transl Med       Date:  2012-12-17       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.